Thierry Alcindor

Thierry Alcindor

McGill University - Montréal / Canada
Medical and Health Sciences / Medical Oncology
AD Scientific Index ID: 648970
person_outline Thierry Alcindor's MOST POPULAR ARTICLES
1-) Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trialI Judson, J Verweij, H Gelderblom, JT Hartmann, P Schöffski, JY Blay, ...The lancet oncology 15 (4), 415-423, 20148082014
2-) Oxaliplatin: a review in the era of molecularly targeted therapyT Alcindor, N BeaugerCurrent oncology 18 (1), 18-25, 20114052011
3-) 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancerD Farge, C Frere, JM Connors, C Ay, AA Khorana, A Munoz, B Brenner, ...The Lancet Oncology 20 (10), e566-e581, 20193262019
4-) Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trialWD Tap, H Gelderblom, E Palmerini, J Desai, S Bauer, JY Blay, T Alcindor, ...The Lancet 394 (10197), 478-487, 20193612019
5-) Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre …WD Tap, Z Papai, BA Van Tine, S Attia, KN Ganjoo, RL Jones, S Schuetze, ...The lancet oncology 18 (8), 1089-1103, 20172862017